title: [Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
abstract: Emesis in chemotherapy containing Cisplatinum (DDP) is still a therapeutical dilemma. Emesis and nausea cause the cessation of a potential curative therapy in up to 10% of patients treated with DDP. We studied the antiemetic effectiveness of the selective Serotonin (5HT3)-receptor-antagonist Ondansetron (GR 38032F, Glaxo) in patients receiving high dose platinum chemotherapy. All patients suffered from severe emesis and were refractory to any standard antiemetic regimen (Metoclopramid). We studied the efficacy of the new drug against acute and delayed emesis following platinum chemotherapy. All adverse events are listed. Thirty four courses (n = 17 patients) of a platinum-containing regimen were analyzed so far. A sufficient antiemetic efficacy was observed in 56% of the courses. In 32 of 34 course (94%) the patients preferred the new drug compared with the standard antiemetic regime (Metoclopramid). In most cases only minor adverse events--which do not require any medical therapy--occurred. The most common adverse events were headache, constipation, dry mouth, abdominal discomfort and elevation of liver enzyme level without any clinical symptoms. One patient needed bowel surgery for severe constipation based on widespread intra-abdominal carcinosis.
authors: Universitäts-Frauenklinik Freiburg.
authors: A
authors: A
authors: du Bois
authors: H G
authors: HG
authors: Meerpohl
authors: C
authors: C
authors: Wilhelm
authors: L
authors: L
authors: Quaas
authors: I
authors: I
authors: Barnickel
authors: A
authors: A
authors: Pfleiderer
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D017294:Ondansetron; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012702:Serotonin Antagonists; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000932:Antiemetics; D007093:Imidazoles; D012702:Serotonin Antagonists; D017294:Ondansetron; D002945:Cisplatin
vernacular_title: Therapierefraktäre Emesis unter Cisplatin. Prospektive Studie mit dem Serotonin-Rezeptor Antagonist GR 38032F.